Heart drug trial offers hope for long COVID sufferers
NCT ID NCT05697640
Summary
This study is testing whether a drug called vericiguat, already approved for heart failure, can help people with Long COVID who have severe fatigue. About 104 adults aged 18-50 will take either the drug or a placebo pill for 10 weeks to see if it improves their physical function and energy levels. The main goal is to see if the treatment can make daily activities like walking and climbing stairs easier.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-COVID ME/CFS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.